Personalized pharmacotherapy: Genotypes, biomarkers, and beyond

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 2, 2009, Pages 142-

  Gurwitz, D ^a   Lunshof, J E ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

GENOTYPE; LETTER; PATIENT CARE; PHARMACEUTICAL CARE; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; CONTINENTAL POPULATION GROUPS; DRUG THERAPY; GENOTYPE; HUMANS; PHARMACOGENETICS;

EID: 58549116131     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.228     Document Type: Letter

References (5)

1. Ng, P.C., Zhao, Q., Levy, S., Strausberg, R.L. & Venter, J.C. Individual genomes instead of race for personalized medicine. Clin. Pharmacol. Ther. 84, 306-309 (2008).
2. Baird, K.L. The new NIH and FDA medical research policies: targeting gender, promoting justice. J. Health Polit. Policy Law 24, 531-565 (1999).
3. McLeod, H.L. Pharmacogenetics: more than skin deep. Nat. Genet. 29, 247-248 (2001).
4. Lunshof, J. & de Wert, G. Pharmacogenomics, drug development, and ethics: some points to consider. Drug Dev. Res. 62, 112-116 (2004).
5. Lunshof, J.E., Pirmohamed, M. & Gurwitz, D. Personalized medicine: decades away? Pharmacogenomics 7, 237-241 (2006).